Genome&Company Inc is a Korea-based company primarily engaged in the business of new drug development. The Company operates its business through three segments. The New Drug Development segment primarily develops anticancer drugs and microbiome medicines. The Contract Development and Manufacturing Organization (CDMO) segment primarily provides microbiome therapeutic contract development and manufacturing organization services. The Consumer segment primarily engages in the microbiome cosmetics and health functional food business.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
03/07/26	₩3,760.00	+1.21%	395,557
02/07/26	₩3,715.00	-9.61%	258,727
01/07/26	₩4,110.00	+6.48%	331,185
30/06/26	₩3,860.00	+0.65%	428,650
29/06/26	₩3,835.00	+7.27%	693,499

End-of-day quote Korea S.E.

More quotes

Income Statement and Estimates

More financial data

End-of-day quote Korea S.E. Other stock markets 03/07/2026			5-day change	1st Jan Change
3,760.00 ^KRW	+1.21%		+5.17%	-45.35%

04-13	Genome & Company announced that it has received KRW 6.99999414 billion in funding	CI
04-02	Genome & Company announced that it expects to receive KRW 6.99999414 billion in funding	CI

Market Cap	170B 111M 97.17M 89.35M 83.24M 158M 10.57B 160M 1.07B 417M 5.2B 417M 408M 17.98B	P/E 2024	-4.17x	P/E 2025	-33.5x
Enterprise Value	152B 99.41M 86.95M 79.96M 74.48M 141M 9.46B 143M 958M 373M 4.65B 373M 365M 16.09B	EV / Sales 2024	1.31x	EV / Sales 2025	8.97x
Free-Float	82.77%	Yield 2024 *	-	Yield 2025	-

04-13	Genome & Company announced that it has received KRW 6.99999414 billion in funding	CI
04-02	Genome & Company announced that it expects to receive KRW 6.99999414 billion in funding	CI
03-12	Genome & Company announced that it has received KRW 29.99998254 billion in funding from DongKoo Bio & Pharma Co., Ltd.	CI
22/09/25	Genome & Company(KOSDAQ:A314130) dropped from S&P Global BMI Index	CI
20/08/25	An undisclosed buyer agreed to acquire 40.12% stake in List Biotherapeutics, Inc. from Genome & Company for $19.1 million.	CI
10/07/25	Genome & Company announced that it has received KRW 25.7890592 billion in funding	CI
27/04/25	Genome & Company announced that it has received KRW 27.066097613 billion in funding from a group of investors	CI
23/04/25	Genome & Company announced that it expects to receive KRW 27.066097613 billion in funding from a group of investors	CI
23/04/25	Genome & Company announced that it expects to receive KRW 27.06426965 billion in funding	CI
23/04/25	Genome & Company agreed to acquire an additional 28.64% stake in List Biotherapeutics, Inc. from a group of shareholders for KRW 27.07 billion.	CI
18/07/24	Genome & Company announced that it has received KRW 4.5 billion in funding from Paratus New Normal CB Private Equity Fund Co., Ltd, Susung Asset Management Co., Ltd.	CI
16/07/24	Genome & Company announced that it expects to receive KRW 4.5 billion in funding from Paratus New Normal CB Private Equity Fund Co., Ltd, Susung Asset Management Co., Ltd.	CI
24/01/24	Genome & Company Announces Positive Topline Results from Phase 2 Clinical Trial of Combination of GEN-001 and Bavencio®? for the Treatment of Gastric Cancer Poster Presented at ASCO GI	CI

1 day	+1.21%
1 week	+5.17%
Current month	-2.59%
1 month	-35.95%
3 months	-48.14%
6 months	-51.17%
Current year	-45.35%

Genome & Company Share Price

Stocks

A314130

KR7314130006

Biotechnology & Medical Research

Valuation: Genome & Company

Chart: Genome & Company

Latest news : Genome & Company

Quotes and Performance

Course Extremes

Managers and Directors: Genome & Company

Latest insider transactions

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Income Statement and Estimates

1 week	3,520	4,175
1 month	3,510	6,130
Current year	3,510	10,180
1 year	2,440	10,180
3 years	2,170	10,180
5 years	2,170	28,800
10 years	2,170	47,500

Manager	Title	Age	Since
Han-Su Park CEO	Chief Executive Officer	53	23/09/2015
Ji-Soo Bae CEO	Chief Executive Officer	55	23/09/2015

Director	Title	Age	Since
Ji-Soo Bae BRD	Director/Board Member	55	23/09/2015
Yu-Seok Hong BRD	Director/Board Member	62	-
Gyu-Yeon Lee BRD	Director/Board Member	62	27/03/2025

Date	Insider	Type	Main position	Quantity	% Market Cap.
08/05/25	Jin-kyung Seo	Free		10,000	0.0322%
08/05/25	Byung-Gyu Park	Free	Public Communications Manager	50,000	0.1608%
08/05/25	Ji-Soo Bae	Don	Founder	90,000	0.2895%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
GENOME & COMPANY	+1.21%	+5.17%	+23.08%	-55.76%	111M
LONZA GROUP AG	+1.70%	+7.41%	+2.50%	+8.22%	49.92B
REVOLUTION MEDICINES, INC.	+0.92%	+3.93%	+399.71%	+605.33%	40.23B
IQVIA HOLDINGS INC.	+1.89%	+8.32%	+26.06%	-6.35%	34.55B
BEONE MEDICINES AG	+2.38%	+6.35%	+21.25%	+64.58%	33.09B
CELLTRION, INC.	+3.96%	+10.67%	+8.30%	+40.44%	27.51B
ASCENDIS PHARMA A/S	+2.51%	+5.27%	-	-	17.05B
MEDPACE HOLDINGS, INC.	+2.58%	+5.79%	+73.44%	+133.27%	15.92B
EUROFINS SCIENTIFIC SE	+0.32%	+0.58%	+14.00%	+19.59%	13.86B
IONIS PHARMACEUTICALS, INC.	+3.30%	+0.76%	+90.23%	+99.12%	13.52B
Average	+2.08%	+5.05%	+73.17%	+100.94%	24.58B
Weighted average by Cap.	+2.07%	+6.53%	+90.17%	+137.81%

	2024	2025
Net sales	27.74B 18.15M 15.87M 14.59M 13.59M 25.77M 1.73B 26.16M 175M 68.06M 849M 68.09M 66.64M 2.94B	24.59B 16.08M 14.06M 12.93M 12.05M 22.84M 1.53B 23.19M 155M 60.31M 752M 60.34M 59.06M 2.6B
Net income	-20.11B -13.15M -11.5M -10.58M -9.86M -18.68M -1.25B -18.97M -127M -49.34M -615M -49.36M -48.31M -2.13B	-6.43B -4.2M -3.68M -3.38M -3.15M -5.97M -400M -6.06M -40.53M -15.77M -197M -15.77M -15.44M -680M
Net Debt	-48.91B -31.98M -27.97M -25.72M -23.96M -45.43M -3.04B -46.12M -308M -120M -1.5B -120M -117M -5.18B	-17.86B -11.68M -10.22M -9.4M -8.75M -16.59M -1.11B -16.84M -113M -43.82M -547M -43.83M -42.91M -1.89B